PulseAI's wearable arrhythmia AI model clears FDA 510(k) review

PulseAI, a Belfast-headquartered medtech company founded in 2020, announced on Nov. 5 that the FDA granted 510(k) clearance to its AI-powered arrhythmia analysis model for wearable ECG data, according to the company's press release. Irish outlet The Business Post independently reported the clearance the same day, noting it positions the company's software as a regulated AI layer that device makers can plug into existing wearable hardware rather than a new device in its own right. In a 296-participant study published in the journal Heart Rhythm, PulseAI's algorithm improved atrial fibrillation detection sensitivity while cutting inconclusive interpretations by 92% compared with the Apple Watch's built-in algorithm.

The clearance doesn't attach to a single consumer device — it's a cloud-based analysis layer. Recordings captured by a compatible ECG sensor are submitted to PulseAI's service, analyzed, and the structured result is returned to whatever application sits on top. That architecture means the clinical value lives in the API contract, not in any one app shell, and it puts the integration burden squarely on the companion software: a patient-facing or clinician-facing app has to request a reading, handle the async response, and render a result a non-specialist can act on — consistently, on both iOS and Android, since cardiology patients skew toward whichever phone they already carry.

Why the companion app matters as much as the clearance

A cleared AI model is only as useful as the interface patients and clinicians actually touch. Device makers building around an API like PulseAI's are effectively committing to ship and maintain a cross-platform app: onboarding a patient's wearable, surfacing a cleared-software result without over-promising diagnosis, and keeping that experience in sync across two mobile operating systems that update their health-data APIs on different schedules. Teams that try to hand iOS and Android to separate native codebases usually end up with the result-rendering logic drifting apart within a year — exactly the kind of maintenance gap a Flutter development team is built to close, shipping one shared UI and business-logic layer that reads a cleared AI vendor's API the same way on both platforms.

What this means for device makers evaluating a similar path

PulseAI's clearance is another data point in a pattern this site has tracked for months: FDA increasingly clears the algorithm, not the hardware, letting companies extract regulated clinical value from a sensor that already exists. For a device maker weighing whether to pursue a comparable software-only pathway, the harder engineering problem usually isn't the regulatory submission — it's building and maintaining the mobile layer that makes the cleared output usable in a clinic or a patient's living room without a second platform-specific rebuild six months later.